The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Leading orthopaedic experts call for equitable insurance coverage to patients for accessing advanced, precision-driven joint replacement technologies
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
Subscribe To Our Newsletter & Stay Updated
